Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia

INTRODUCTION: Imatinib mesylate (IM), a selective inhibitor of the BCR-ABL tyrosine kinase, is a well-established first-line treatment for chronic myeloid leukemia (CML). IM is metabolized mainly by cytochrome P450 (CYP) in the liver, specifically the CYP3A4 and CYP3A5 enzymes. Polymorphisms in thes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Ther
Egile Nagusiak: Maddin, Najlaa, Husin, Azlan, Gan, Siew Hua, Aziz, Baba Abdul, Ankathil, Ravindran
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2016
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315081/
https://ncbi.nlm.nih.gov/pubmed/28261657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0035-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak